Misoprostol compared with methylergometrine for the prevention of postpartum haemorrhage: a double-blind randomised trial

Objective To compare the: efficacy and side effects of misoprostol, compare d with methylergometrine, for the prevention of postpartum haemorrhage. Design A double-blind, randomised clinical trial of 200 women with apparent ly normal pregnancies. Setting University teaching hospital. Participants Two hundred women with apparently normal pregnancies. Methods After the baby had been born, all women received two capsules by mo uth and the contents of an ampule by intravenous injection. Each woman only received one active product. The capsules contained either a total of 600 mu g misoprostol or placebo, and the ampule 200 mu g of methylergometrine o r placebo. Main outcome measures Need for further oxytocic drugs, blood pressure, the presence of side effects, mean haemoglobin and haematocrit three days after delivery. Results Two hundred women completed the study (100 received methylergometri ne and 100 misoprostol). Postpartum haemorrhage occurred in 4.3% of the met hylergometrine group and 8.3% of the misoprostol group (P = 0.57). The need for further oxytocic drugs was 4.4% and 12.8% after methylergometrine and misoprostol, respectively (P = 0.065). One hour after the birth of the baby there was no difference in the mean systolic blood pressure (117 +/- 12 mm Hg versus 115 +/- 11 mmHg) (P = 0.26) or the mean diastolic blood pressure (72 +/- 10 mmHg versus 71 +/- 11 mmHg for the groups receiving methylergome trine or misoprostal, respectively) (P = 0.97). The mean temperature in the misoprostol group rose to 37 degrees C, compared with 37 degrees C in the methylergometrine group (P < 0.0001). In the misoprostol group 34% develope d fever (> 38 degrees C) compared with 3% in the methylergometrine group (P < 0.0001). Shivering (visual analogue score greater than or equal to 8) al so occurred more often after misoprostol (42%) than after methylergometrine (8.5%) (P < 0.0001). The haemoglobin level (g/dL) on the third postpartum day was similar for bath groups (11.0 and 11.2 for methylergometrine and mi soprostol, respectively) (P = 0.39). Conclusions This study suggests that although protection from postpartum ha emorrhage using par enteral methylergometrine and oral misoprostol is nearl y equal, misoprostol is associated with more side effects.